JP2021513355A5 - - Google Patents
Info
- Publication number
- JP2021513355A5 JP2021513355A5 JP2020543344A JP2020543344A JP2021513355A5 JP 2021513355 A5 JP2021513355 A5 JP 2021513355A5 JP 2020543344 A JP2020543344 A JP 2020543344A JP 2020543344 A JP2020543344 A JP 2020543344A JP 2021513355 A5 JP2021513355 A5 JP 2021513355A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cedna vector
- vector according
- nucleotide sequence
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024141968A JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630670P | 2018-02-14 | 2018-02-14 | |
| US201862630676P | 2018-02-14 | 2018-02-14 | |
| US62/630,670 | 2018-02-14 | ||
| US62/630,676 | 2018-02-14 | ||
| US201862680087P | 2018-06-04 | 2018-06-04 | |
| US201862680092P | 2018-06-04 | 2018-06-04 | |
| US62/680,092 | 2018-06-04 | ||
| US62/680,087 | 2018-06-04 | ||
| PCT/US2019/018016 WO2019161059A1 (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024141968A Division JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513355A JP2021513355A (ja) | 2021-05-27 |
| JP2021513355A5 true JP2021513355A5 (enExample) | 2022-02-22 |
Family
ID=67619630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543344A Pending JP2021513355A (ja) | 2018-02-14 | 2019-02-14 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
| JP2024141968A Pending JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024141968A Pending JP2024167281A (ja) | 2018-02-14 | 2024-08-23 | 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220042035A1 (enExample) |
| EP (1) | EP3752191A4 (enExample) |
| JP (2) | JP2021513355A (enExample) |
| KR (1) | KR20200120649A (enExample) |
| CN (1) | CN111818942A (enExample) |
| AU (1) | AU2019221642A1 (enExample) |
| BR (1) | BR112020016288A2 (enExample) |
| CA (1) | CA3091250A1 (enExample) |
| IL (1) | IL276469A (enExample) |
| MA (1) | MA51842A (enExample) |
| MX (1) | MX2020008470A (enExample) |
| PH (1) | PH12020551039A1 (enExample) |
| SG (1) | SG11202006431WA (enExample) |
| WO (1) | WO2019161059A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| JP2021511047A (ja) | 2018-01-19 | 2021-05-06 | ジェネレーション バイオ カンパニー | 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| CN114929205B (zh) * | 2019-09-06 | 2024-09-03 | 世代生物公司 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
| DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| IL296662A (en) * | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| JP2022108271A (ja) * | 2021-01-12 | 2022-07-25 | Ｊｃｒファーマ株式会社 | リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子 |
| CA3206107A1 (en) * | 2021-01-26 | 2022-08-04 | Brian Furmanski | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same |
| JP2024515788A (ja) * | 2021-04-27 | 2024-04-10 | ジェネレーション バイオ カンパニー | 治療抗体を発現する非ウイルスｄｎａベクター及びその使用 |
| WO2022236016A1 (en) * | 2021-05-07 | 2022-11-10 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| US20260167928A1 (en) * | 2021-11-18 | 2026-06-18 | The Brigham And Women's Hospital, Inc. | Induced proteinopathy models |
| EP4455298A4 (en) * | 2021-12-23 | 2026-01-14 | Takeda Pharmaceuticals Co | METHOD FOR PREDICTING THE RATE OF GENE TRANSFER |
| CN118186005A (zh) * | 2022-12-12 | 2024-06-14 | 苏州荷光科汇生物科技有限公司 | 一种适于阿达木单抗的表达盒及其载体与应用 |
| US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| CN116549632B (zh) * | 2023-03-28 | 2024-09-10 | 中国人民解放军军事科学院军事医学研究院 | 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物 |
| CN121127502A (zh) * | 2023-05-15 | 2025-12-12 | 宜明凯尔生物医药技术(上海)有限公司 | 用于治疗肺高压的重组融合蛋白 |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465583B2 (en) * | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| EP1427744B1 (en) * | 2001-08-27 | 2007-12-26 | Genentech, Inc. | A system for antibody expression and assembly |
| GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
| JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP2970966A4 (en) * | 2013-03-15 | 2016-10-26 | Univ North Carolina | SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES |
| KR102234695B1 (ko) * | 2014-02-06 | 2021-04-02 | 젠자임 코포레이션 | 황반 변성을 치료하고 예방하기 위한 조성물 및 방법 |
| US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| IL261524B2 (en) * | 2016-03-03 | 2023-10-01 | Univ Massachusetts | End-capped linear double-stranded DNA for non-viral gene transfer |
| US11549125B2 (en) * | 2017-08-09 | 2023-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof |
| EP3679148A4 (en) * | 2017-09-08 | 2021-06-09 | Generation Bio Co. | LIPID NANOPARTICLE FORMULATIONS FROM NONVIRAL, CAPSID-FREE DNA VECTORS |
| CA3075168A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Modified closed-ended dna (cedna) |
| KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
| JP2021505159A (ja) * | 2017-12-06 | 2021-02-18 | ジェネレーション バイオ カンパニー | 修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集 |
| JP2021511047A (ja) * | 2018-01-19 | 2021-05-06 | ジェネレーション バイオ カンパニー | 無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス |
| CA3092459A1 (en) * | 2018-03-02 | 2019-09-06 | Generation Bio Co. | Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes |
-
2019
- 2019-02-14 AU AU2019221642A patent/AU2019221642A1/en not_active Abandoned
- 2019-02-14 WO PCT/US2019/018016 patent/WO2019161059A1/en not_active Ceased
- 2019-02-14 CN CN201980013028.XA patent/CN111818942A/zh active Pending
- 2019-02-14 MA MA051842A patent/MA51842A/fr unknown
- 2019-02-14 BR BR112020016288-4A patent/BR112020016288A2/pt not_active Application Discontinuation
- 2019-02-14 KR KR1020207024274A patent/KR20200120649A/ko not_active Ceased
- 2019-02-14 CA CA3091250A patent/CA3091250A1/en active Pending
- 2019-02-14 JP JP2020543344A patent/JP2021513355A/ja active Pending
- 2019-02-14 SG SG11202006431WA patent/SG11202006431WA/en unknown
- 2019-02-14 US US16/968,990 patent/US20220042035A1/en not_active Abandoned
- 2019-02-14 EP EP19753655.0A patent/EP3752191A4/en active Pending
- 2019-02-14 MX MX2020008470A patent/MX2020008470A/es unknown
-
2020
- 2020-07-03 PH PH12020551039A patent/PH12020551039A1/en unknown
- 2020-08-03 IL IL276469A patent/IL276469A/en unknown
-
2024
- 2024-08-23 JP JP2024141968A patent/JP2024167281A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210324343A1 (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| AU2018291023B2 (en) | AAV vector column purification methods | |
| JP2021513999A5 (enExample) | ||
| JP2022033855A5 (enExample) | ||
| CA2379564C (en) | Structural protein of adeno-associated virus with modified chromatographic properties, its production and use | |
| JP2018526003A (ja) | イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ | |
| JP2008506389A (ja) | Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法 | |
| JP7410522B2 (ja) | 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達 | |
| JP2022523679A5 (enExample) | ||
| Demircan et al. | T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8 | |
| RU2014146159A (ru) | Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav | |
| JP2022520803A5 (enExample) | ||
| JP2017506230A5 (enExample) | ||
| RU2016135771A (ru) | Композиции и способы лечения и предотвращения дегенерации желтого пятна | |
| JP2024509251A5 (enExample) | ||
| JP2023520763A5 (enExample) | ||
| AR123948A1 (es) | ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES | |
| JP2021511020A5 (enExample) | ||
| Youjin et al. | The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy | |
| US20240050476A1 (en) | Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer | |
| JP2023504201A5 (enExample) | ||
| McConnell et al. | Generation Of Potent And High-Yield Exosome-Associated AAV (exoAAV) Using Engineered Exosomes | |
| CA2975569C (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| AU2024290842A1 (en) | Engineered aav capsid proteins | |
| RU2020130010A (ru) | Невирусные днк-векторы и их применение для продуцирования антител и слитых белков |